Innovation Focused
Creative solutions backed by solid experience and the latest industry know-how.
Global Perspective
We work with some of the largest bio-pharma companies across the globe.
Strong Network
Our extensive experience in the bio-pharma space has helped us develop a robust network of industry leaders and experts.
Our Services
The global bio-pharma industry is perpetually evolving in the search for breakthrough therapies, curative drugs, and new treatment pathways.
Bio-pharma companies are expanding both organically and inorganically to achieve better healthcare outcomes and access.
The healthcare industry is knowledge- and tech-driven, and we ensure that we are at the forefront of it all.
Our Research Services include: Therapeutic Class Research, Industry Themes, Perspectives
Research
Therapeutic Class Research
New treatment pathways may sometimes entirely change the competitive landscape and other market dynamics, and hence, call for meaningful research and analysis. We provide insightful research on new therapies and their potential impacts on patient outcomes as well as company performance in order for our clients to make informed decisions in the area.
Industry Themes
As industry players work in a tireless pursuit to solve some of the most challenging puzzles, we assess interesting aspects of markets within markets, such as drivers, challenges, and competition, based on themes like drugs, patents, and filings, enabling firms to gather insights and identify rewarding opportunities.
- MP Group: Outlook on the CROs for the new-age Biopharma
- MP Group: Outlook on the mRNA Bio-CDMOs – A key catalyst for the evolution of mRNA therapeutics
- MP Group – A Global Outlook of HEOR (Health Economics and Outcomes Research) Services
- Digital Health Innovation: key stakeholders empowering the ecosystem
- MP Group: Outlook on ‘Promise of Digital Health-2022’
- MP Group: Outlook on ‘Artificial Intelligence in Target and Biomarker Discovery-2022′
- MP Group: Outlook on ‘AI and medical writing’
- MP Group: Outlook on Microphysiological Systems (MPS) – The future of pre-clinical R&D
- MP Group - Natural Language Processing: An AI tool to cash-in the ‘big-text’ in life sciences
- MP Outlook – 2021 and Beyond
- MP Group – AI toolkit for early-stage drug discovery
- MP Group - Next Generation CROs – Differentiated Technologies Today That Will Pay-Off Tomorrow
- MP Group – Outlook of Protein Formulation Technologies – Opportunities for IV to subQ Conversion
- MP Group – Overview of Biobetters: IV to SC formulation conversion for patient compliance, healthcare savings, and market differentiation
- Japan Biosimilars: Landscape Today, Outlook Tomorrow – ‘Biosame’ entry, uninterrupted supply and companies’ strong front-end footprint requirements make it a distinct market
- MP Group – Biosimilars Landscape – China and India
- MP Group – Global Biosimilars Outlook, 2019
- MP Group - Biosimilars Landscape - USA
- MP Advisors/Mehta Partners: Global Biosimilars Outlook -2019 & Beyond
- Indian BioPharma Landscape – 2018
- MP Group – Overview of Biobetters: IV to SC formulation conversion for patient compliance, healthcare savings, and market differentiation
Perspectives
Having been in the business of consulting our esteemed biopharma clients for decades, it gives us immense pleasure to contribute to the global knowledge pool and exert a positive influence on the advancement of this industry. We do so through our ideas and perspectives on recent events, deals, breakthrough drugs, and other themes.
- Pharmaphorum: Global upswing in medical writing, with a bout of M&A
- Biopharma Trend : 7 Tips for Growing a Successful ‘AI in Pharma’ Business: Key Growth Strategy Lessons
- Biopharma Trend Article: Tech Providers or Biotechs: The Quest to Find an Optimal Business Model Continues for AI Drug Discovery Companies…
- Biopharma Insights Article: The AI Productivity Game in Pharma
- BioSpectrum Article – Time for Asian pharma to up their AI game!
- BioSpectrum Article -Face-lifting biopharma industry image
- 5 pitfalls AI healthcare start-ups need to avoid
- Mehta Analysis: The Promise Of 2021
- How AI is fighting COVID-19: the companies using intelligent tech to find new drugs
- Mehta Analysis: The New Decade Is Sure to Transform Biopharma Globally
- Mehta Analysis: Who Will Speak Out As Regulators Are Politicized?
- Mehta Analysis: What Can Tesla Teach Pharma?
- Mehta Analysis: What Do Facebook Libra And Democrats At Presidential Debates Have In Common?
- Mehta Analysis: Welcome to BioPharma 2.0
- Mehta Analysis: Two Pillars of Industry
- BioSpectrum Article - Time for Asian pharma to up their AI game!
Landmark Transactions
Our Team
